Synergistic Cell-Targeting Systems

Publication ID: 24-11857628_0008_PTD

Published: October 28, 2025

Category:Synergistic Combinations

Legal Citation

pr1or.art Inc., “Synergistic Cell-Targeting Systems,” Published Technical Disclosure No. 24-11857628_0008_PTD, Published October 28, 2025, available at https://archive.pr1or.art/24-11857628_0008_PTD

This technical disclosure describes improvements that would be readily apparent to a Person Having Ordinary Skill In The Art (PHOSITA) when considered in combination with the foundational architecture disclosed in U.S. Patent No. 11,857,628.

Summary of the Inventive Concept

The present inventive concept integrates Shiga toxin effector polypeptides with distinct technologies such as AI, IoT, blockchain, and nanomaterials to create novel, more powerful systems for targeted conjugation and personalized medicine.

Background and Problem Solved

The original patent disclosed cell-targeting molecules with Shiga toxin effector polypeptides, but these molecules had limitations in terms of tracking, optimization, and delivery. The new inventive concept addresses these limitations by incorporating synergistic combinations of technologies to enhance the efficacy and versatility of cell-targeting molecules.

Detailed Description of the Inventive Concept

The new inventive concept comprises systems and methods that integrate Shiga toxin effector polypeptides with AI-powered optimization algorithms, blockchain-based tracking modules, IoT-based sensor networks, and nanomaterial-based delivery systems. These combinations enable real-time monitoring of target biomolecule binding, personalized medicine, and targeted release of therapeutic agents. For example, the system of claim 1 integrates a cell-targeting molecule with a blockchain-based tracking module, allowing for secure and transparent monitoring of target biomolecule binding. The method of claim 2 utilizes an AI-powered optimization algorithm to select target biomolecules for a cell-targeting molecule, ensuring optimal efficacy.

Novelty and Inventive Step

The new claims introduce novel and non-obvious combinations of Shiga toxin effector polypeptides with distinct technologies, providing a synergistic effect that enhances the functionality and versatility of cell-targeting molecules. The inventive step lies in the recognition of the potential benefits of integrating these technologies and the development of systems and methods that realize these benefits.

Alternative Embodiments and Variations

Alternative embodiments of the inventive concept could include the use of different AI algorithms, blockchain platforms, or nanomaterials. Variations could also include the integration of additional technologies, such as CRISPR gene editing or quantum computing, to further enhance the functionality of cell-targeting molecules.

Potential Commercial Applications and Market

The inventive concept has significant commercial potential in the fields of personalized medicine, targeted therapy, and biomedical research. The integration of AI, IoT, blockchain, and nanomaterials could lead to the development of novel therapeutic agents, diagnostic tools, and research platforms, addressing a market estimated to be worth billions of dollars.

CPC Classifications

Section	Class	Group
A	A61	A61K45/06
A	A61	A61K38/00
A	A61	A61K38/164
A	A61	A61K47/6829
C	C07	C07K14/195
C	C07	C07K14/25
A	A61	A61K2039/6037
C	C07	C07K2319/05
C	C07	C07K2319/55

Section 103 Obviousness Analysis (PHOSITA)

▼

Field of Art

Biotechnology and molecular medicine, specifically focused on cell-targeting molecules, protein engineering, and targeted therapeutic delivery systems. Requires advanced knowledge of protein biochemistry, molecular biology, and bioconjugation techniques

Person of Ordinary Skill (PHOSITA) Profile

A researcher with a PhD in molecular biology or bioengineering, experienced in protein modification, conjugation strategies, and therapeutic molecule design. Familiar with computational biology tools and interdisciplinary biotechnology approaches

Obviousness Rationale

A PHOSITA would recognize that integrating emerging technologies like AI, blockchain, and IoT with existing cell-targeting molecule platforms represents a predictable extension of current biotechnological research trends. The core Shiga toxin effector polypeptide structure remains fundamentally unchanged, with technological additions providing enhanced monitoring and optimization capabilities. These combinations represent logical incremental innovations that would be apparent to a skilled practitioner seeking to improve therapeutic targeting and tracking methodologies.

Obvious Combinations & Variations

Source Patent Element

Shiga toxin effector polypeptide with site-specific amino acid modifications

PTD Variation

Integration of AI-powered optimization algorithms for selecting and modifying target biomolecule binding regions

Obviousness Reasoning

Computational protein design is a well-established technique, and applying machine learning to protein engineering represents a predictable technological progression with known potential for systematic optimization

Source Patent Element

Cell-targeting molecule with specific linker peptide configurations

PTD Variation

Blockchain-based tracking module for monitoring target biomolecule binding interactions

Obviousness Reasoning

Tracking and verifying molecular interactions is a standard requirement in biotechnology, and blockchain provides a transparent, secure method for recording such data that would be an obvious technological enhancement

Source Patent Element

Targeted conjugation of Shiga toxin effector polypeptides

PTD Variation

Nanomaterial-based delivery systems for targeted release of therapeutic agents

Obviousness Reasoning

Nanomaterial drug delivery is a known strategy in biotechnology, and applying such delivery mechanisms to existing cell-targeting molecules represents a straightforward technological adaptation with predictable potential for improved therapeutic targeting

Source Patent Element

Specific amino acid substitutions in Shiga toxin effector polypeptides

PTD Variation

IoT-based sensor networks for real-time monitoring of molecular interactions and patient responses

Obviousness Reasoning

Integrating sensor technologies for biological monitoring is a logical extension of existing biotechnological research, representing an incremental improvement in tracking and understanding molecular interactions

35 U.S.C. § 103 Summary: Based on the teachings of US Patent 11857628 and the disclosed technological variations, a Person Having Ordinary Skill In The Art would find the proposed cell-targeting molecule systems and methods obvious and lacking inventive step. The integration of computational, blockchain, IoT, and nanomaterial technologies with existing Shiga toxin effector polypeptide platforms represents a predictable combination of known techniques that would not rise to the level of non-obvious innovation under 35 U.S.C. Section 103.

Original Patent Information

Patent Number	US 11,857,628
Title	Shiga toxin A subunit effector polypeptides, Shiga toxin effector scaffolds, and cell-targeting molecules for site-specific conjugation
Assignee(s)	Molecular Templates, Inc.